CL2022001741A1 - Compuestos cíclicos y métodos de uso de estos - Google Patents
Compuestos cíclicos y métodos de uso de estosInfo
- Publication number
- CL2022001741A1 CL2022001741A1 CL2022001741A CL2022001741A CL2022001741A1 CL 2022001741 A1 CL2022001741 A1 CL 2022001741A1 CL 2022001741 A CL2022001741 A CL 2022001741A CL 2022001741 A CL2022001741 A CL 2022001741A CL 2022001741 A1 CL2022001741 A1 CL 2022001741A1
- Authority
- CL
- Chile
- Prior art keywords
- methods
- same
- cyclic compounds
- compounds
- cancer
- Prior art date
Links
- 150000001923 cyclic compounds Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000037979 autoimmune inflammatory disease Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pyrane Compounds (AREA)
- Saccharide Compounds (AREA)
Abstract
La presente solicitud también describe una composición farmacéutica que comprende un compuesto de la Fórmula (I), y sales aceptables desde el punto de vista farmacéuticode este, y métodos para usar los compuestos y las composiciones para tratar enfermedades, tales como cáncer, trastornos autoinmunitarios y trastornos inflamatorios.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962954262P | 2019-12-27 | 2019-12-27 | |
US202063040582P | 2020-06-18 | 2020-06-18 | |
US202063119521P | 2020-11-30 | 2020-11-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2022001741A1 true CL2022001741A1 (es) | 2023-01-27 |
Family
ID=74206185
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2022001741A CL2022001741A1 (es) | 2019-12-27 | 2022-06-24 | Compuestos cíclicos y métodos de uso de estos |
Country Status (13)
Country | Link |
---|---|
US (1) | US20240018157A1 (es) |
EP (1) | EP4081526A1 (es) |
JP (2) | JP2023509886A (es) |
KR (1) | KR20220123023A (es) |
CN (1) | CN114945571A (es) |
AU (1) | AU2020413333A1 (es) |
BR (1) | BR112022012684A2 (es) |
CA (1) | CA3161339A1 (es) |
CL (1) | CL2022001741A1 (es) |
IL (1) | IL294214A (es) |
MX (1) | MX2022007171A (es) |
TW (1) | TW202136270A (es) |
WO (1) | WO2021134004A1 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW202320755A (zh) * | 2021-09-30 | 2023-06-01 | 大陸商上海拓界生物醫藥科技有限公司 | 三環化合物及其製備方法 |
TW202342032A (zh) | 2022-02-02 | 2023-11-01 | 日商小野藥品工業股份有限公司 | 含有malt1抑制劑作為有效成分的癌治療劑 |
TW202417445A (zh) * | 2022-07-22 | 2024-05-01 | 美商薛定諤公司 | 環狀化合物及其使用方法 |
WO2024133859A1 (en) * | 2022-12-23 | 2024-06-27 | Janssen Pharmaceutica Nv | Malt1 inhibitors |
Family Cites Families (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE602004021472D1 (en) | 2003-02-20 | 2009-07-23 | Smithkline Beecham Corp | Pyrimiidinverbindungen |
WO2005099363A2 (en) | 2004-03-26 | 2005-10-27 | Whitehead Institute For Biomedical Research | Methods of diagnosing, preventing and treating cancer metastasis |
GB0512324D0 (en) | 2005-06-16 | 2005-07-27 | Novartis Ag | Organic compounds |
PE20060664A1 (es) | 2004-09-15 | 2006-08-04 | Novartis Ag | Amidas biciclicas como inhibidores de cinasa |
WO2007002433A1 (en) | 2005-06-22 | 2007-01-04 | Plexxikon, Inc. | Pyrrolo [2, 3-b] pyridine derivatives as protein kinase inhibitors |
EA015126B1 (ru) | 2006-03-27 | 2011-06-30 | НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. | Пиридил- и пиримидинилзамещённые производные пиррола, тиофена и фурана в качестве ингибиторов киназ |
PE20121126A1 (es) | 2006-12-21 | 2012-08-24 | Plexxikon Inc | Compuestos pirrolo [2,3-b] piridinas como moduladores de quinasa |
EP2094701A2 (en) | 2006-12-21 | 2009-09-02 | Plexxikon, Inc. | Compounds and methods for kinase modulation, and indications therefor |
WO2008079909A1 (en) | 2006-12-21 | 2008-07-03 | Plexxikon, Inc. | Pyrrolo [2,3-b] pyridines as kinase modulators |
JP2010533158A (ja) | 2007-07-09 | 2010-10-21 | アストラゼネカ アクチボラグ | 化合物類−945 |
CN101808994B (zh) | 2007-07-17 | 2013-05-15 | 普莱希科公司 | 用于激酶调节的化合物和方法以及其适应症 |
AU2008279776B2 (en) | 2007-07-19 | 2013-05-23 | Merck Sharp & Dohme Corp. | Heterocyclic amide compounds as protein kinase inhibitors |
CA2705694C (en) * | 2007-11-21 | 2015-02-24 | Katholieke Universiteit Leuven, K.U.Leuven R & D | Inhibitors of malt1 proteolytic activity and uses thereof |
US8598172B2 (en) | 2007-12-04 | 2013-12-03 | Nerviano Medical Sciences S.R.L. | Substituted dihydropteridin-6-one derivatives, process for their preparation and their use as kinase inhibitors |
WO2009118411A2 (en) | 2008-03-28 | 2009-10-01 | Nerviano Medical Sciences S.R.L. | 3,4-dihydro-2h-pyrazino[1,2-a]indol-1-one derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
PE20091846A1 (es) | 2008-05-19 | 2009-12-16 | Plexxikon Inc | DERIVADOS DE PIRROLO[2,3-d]-PIRIMIDINA COMO MODULADORES DE CINASAS |
WO2009143018A2 (en) | 2008-05-19 | 2009-11-26 | Plexxikon, Inc. | Compounds and methods for kinase modulation, and indications therefor |
JP5351254B2 (ja) | 2008-05-23 | 2013-11-27 | ノバルティス アーゲー | キノキサリン−およびキノリン−カルボキシアミド誘導体 |
AU2009257635A1 (en) | 2008-06-10 | 2009-12-17 | Plexxikon, Inc. | 5H-Pyrrolo [2,3-b] pyrazine derivatives for kinase modulation, and indications therefor |
WO2010031816A1 (en) | 2008-09-19 | 2010-03-25 | Nerviano Medical Sciences S.R.L. | 3,4 DIHYDRO-2H-PYRROLO[1,2-a]PYRAZIN-1-ONE DERIVATIVES |
JO3265B1 (ar) | 2008-12-09 | 2018-09-16 | Novartis Ag | مثبطات بيريديلوكسى اندولات vegf-r2 واستخدامها لعلاج المرض |
WO2010111527A1 (en) | 2009-03-26 | 2010-09-30 | Plexxikon, Inc. | Pyrazolo [ 3, 4 -b] pyridines as kinase inhibitors and their medical use |
EP3045457B1 (en) | 2009-06-15 | 2018-05-09 | Nerviano Medical Sciences S.r.l. | Substituted pyrimidinylpyrrolopyridinone derivatives, process for their preparation and their use as kinase inhibitors |
EP2528918B1 (en) | 2010-01-29 | 2014-09-10 | Nerviano Medical Sciences S.r.l. | 6,7-dihydroimidazo[1,5-a]pyrazin-8(5h)-one derivatives as protein kinase modulators |
JP2013519706A (ja) | 2010-02-18 | 2013-05-30 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 癌転移を予防するための方法 |
BR112013018515B1 (pt) | 2011-01-26 | 2021-06-29 | Nerviano Medical Sciences S.R.I | Derivados de pirrol tricíclico, processo para sua preparação e seu uso como inibidores da quinase |
JP5925808B2 (ja) | 2011-01-26 | 2016-05-25 | ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ | 三環式誘導体、これらの調製方法およびこれらのキナーゼ阻害剤としての使用 |
AU2012214762B2 (en) | 2011-02-07 | 2015-08-13 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
ES2580961T3 (es) | 2011-02-24 | 2016-08-30 | Nerviano Medical Sciences S.R.L. | Derivados Tiazolilfenil-bencenosulfonamido como Inhibidores de Cinasa |
EP2688890B1 (en) * | 2011-03-22 | 2017-08-30 | Advinus Therapeutics Limited | Substituted fused tricyclic compounds, compositions and medicinal applications thereof |
US9284298B2 (en) | 2011-04-11 | 2016-03-15 | Nerviano Medical Sciences S.R.L. | Pyrazolyl-pyrimidine derivatives as kinase inhibitors |
WO2012143248A1 (en) | 2011-04-19 | 2012-10-26 | Nerviano Medical Sciences S.R.L. | Substituted pyrimidinyl-pyrroles active as kinase inhibitors |
CA2835478C (en) | 2011-05-12 | 2019-02-05 | Nerviano Medical Sciences S.R.L. | Substituted indazole derivatives active as kinase inhibitors |
JP6016915B2 (ja) | 2011-07-28 | 2016-10-26 | ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ | キナーゼ阻害剤として活性なアルキニル置換ピリミジニルピロール |
EP2788350B1 (en) | 2011-10-07 | 2017-12-06 | Nerviano Medical Sciences S.r.l. | 4-ALKYL SUBSTITUTED 3,4-DIHYDROPYRROLO[1,2-a]PYRAZIN-1(2H)-ONE DERIVATIVES AS KINASES INHIBITORS |
ES2639064T3 (es) | 2011-10-07 | 2017-10-25 | Nerviano Medical Sciences S.R.L. | Derivados de 3,4-dihidropirrolo[1,2-a]pirazin-1(2h)-ona sustituidos como inhibidores de cinasa |
US8377946B1 (en) | 2011-12-30 | 2013-02-19 | Pharmacyclics, Inc. | Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors |
WO2014011900A2 (en) | 2012-07-11 | 2014-01-16 | Blueprint Medicines | Inhibitors of the fibroblast growth factor receptor |
ES2726833T3 (es) | 2012-08-02 | 2019-10-09 | Nerviano Medical Sciences Srl | Pirroles sustituidos activos como inhibidores de cinasas |
EP2917214B1 (en) | 2012-11-07 | 2019-08-28 | Nerviano Medical Sciences S.r.l. | Substituted pyrimidinyl and pyridinyl-pyrrolopyridinones, process for their preparation and their use as kinase inhibitors |
BR112015002626A2 (pt) | 2012-11-29 | 2017-09-26 | Yeda Res & Dev | métodos para prevenção de metástases tumorais, tratamento e prognostico do câncer e identificação dos agentes que são inibidores da metástase putativa |
EP2970231A1 (en) | 2013-03-15 | 2016-01-20 | Blueprint Medicines Corporation | Piperazine derivatives and their use as kit modulators |
EP2997030B1 (en) | 2013-05-14 | 2017-08-09 | Nerviano Medical Sciences S.R.L. | Pyrrolo[2,3-d]pyrimidine derivatives, process for their preparation and their use as kinase inhibitors |
EP3004060B1 (en) | 2013-05-30 | 2019-11-27 | Plexxikon Inc. | Compounds for kinase modulation, and indications therefor |
WO2015017528A1 (en) | 2013-07-30 | 2015-02-05 | Blueprint Medicines Corporation | Pik3c2g fusions |
EP3027655B1 (en) | 2013-07-30 | 2019-08-21 | Blueprint Medicines Corporation | Ntrk2 fusions |
CN105658652B (zh) | 2013-10-17 | 2019-04-12 | 蓝图药品公司 | 可用于治疗与kit相关的病症的组合物 |
WO2015058129A1 (en) | 2013-10-17 | 2015-04-23 | Blueprint Medicines Corporation | Compositions useful for treating disorders related to kit |
EP3060560A1 (en) | 2013-10-25 | 2016-08-31 | Blueprint Medicines Corporation | Inhibitors of the fibroblast growth factor receptor |
WO2015108992A1 (en) | 2014-01-15 | 2015-07-23 | Blueprint Medicines Corporation | Heterobicyclic compounds and their use as fgfr4 receptor inhibitors |
UA121206C2 (uk) | 2014-01-24 | 2020-04-27 | Турнінґ Поінт Терапьютикс, Інк. | Діарильні макроцикли як модулятори протеїнкіназ |
WO2015161277A1 (en) | 2014-04-18 | 2015-10-22 | Blueprint Medicines Corporation | Met fusions |
US20170044622A1 (en) | 2014-04-18 | 2017-02-16 | Blueprint Medicines Corporation | Pik3ca fusions |
WO2015191667A1 (en) | 2014-06-10 | 2015-12-17 | Blueprint Medicines Corporation | Pkn1 fusions |
EP3155131B1 (en) | 2014-06-10 | 2020-02-12 | Blueprint Medicines Corporation | Raf1 fusions |
EP3169809B1 (en) | 2014-07-17 | 2020-04-29 | Blueprint Medicines Corporation | Prkc fusions |
EP3169808B1 (en) | 2014-07-17 | 2019-05-22 | Blueprint Medicines Corporation | Trio:tert fusion in cancer |
US10370725B2 (en) | 2014-07-17 | 2019-08-06 | Blueprint Medicines Corporation | FGR fusions |
US9688680B2 (en) | 2014-08-04 | 2017-06-27 | Blueprint Medicines Corporation | Compositions useful for treating disorders related to kit |
JP2017538659A (ja) * | 2014-09-10 | 2017-12-28 | エピザイム インコーポレイテッド | Smyd阻害剤 |
PL3218378T3 (pl) | 2014-11-14 | 2020-10-19 | Nerviano Medical Sciences S.R.L. | Pochodne 6-amino-7-bicyklo-7-deazapuryny jako inhibitory kinaz białkowych |
WO2016081450A1 (en) | 2014-11-18 | 2016-05-26 | Blueprint Medicines Corporation | Prkacb fusions |
WO2017223414A1 (en) * | 2016-06-24 | 2017-12-28 | Incyte Corporation | HETEROCYCLIC COMPOUNDS AS PI3K-γ INHIBITORS |
CA3032334A1 (en) * | 2016-07-29 | 2018-02-01 | Lupin Limited | Substituted thiazolo-pyridine compounds as malt1 inhibitors |
JP7097880B2 (ja) * | 2016-11-01 | 2022-07-08 | コーネル ユニバーシティー | Malt1分解のための化合物 |
WO2018226150A1 (en) * | 2017-06-05 | 2018-12-13 | Medivir Aktiebolag | Pyrazolopyrimidine as malt-1 inhibitors |
-
2020
- 2020-12-24 EP EP20845493.4A patent/EP4081526A1/en active Pending
- 2020-12-24 CN CN202080092668.7A patent/CN114945571A/zh active Pending
- 2020-12-24 MX MX2022007171A patent/MX2022007171A/es unknown
- 2020-12-24 KR KR1020227025562A patent/KR20220123023A/ko unknown
- 2020-12-24 AU AU2020413333A patent/AU2020413333A1/en active Pending
- 2020-12-24 US US17/787,835 patent/US20240018157A1/en active Pending
- 2020-12-24 CA CA3161339A patent/CA3161339A1/en active Pending
- 2020-12-24 JP JP2022539348A patent/JP2023509886A/ja active Pending
- 2020-12-24 WO PCT/US2020/066999 patent/WO2021134004A1/en unknown
- 2020-12-24 BR BR112022012684A patent/BR112022012684A2/pt unknown
- 2020-12-24 IL IL294214A patent/IL294214A/en unknown
- 2020-12-25 TW TW109146204A patent/TW202136270A/zh unknown
-
2022
- 2022-06-24 CL CL2022001741A patent/CL2022001741A1/es unknown
-
2023
- 2023-12-18 JP JP2023212834A patent/JP2024023699A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2023509886A (ja) | 2023-03-10 |
CA3161339A1 (en) | 2021-07-01 |
AU2020413333A1 (en) | 2022-06-16 |
KR20220123023A (ko) | 2022-09-05 |
MX2022007171A (es) | 2022-08-22 |
JP2024023699A (ja) | 2024-02-21 |
WO2021134004A1 (en) | 2021-07-01 |
TW202136270A (zh) | 2021-10-01 |
EP4081526A1 (en) | 2022-11-02 |
US20240018157A1 (en) | 2024-01-18 |
IL294214A (en) | 2022-08-01 |
BR112022012684A2 (pt) | 2023-03-07 |
CN114945571A (zh) | 2022-08-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2022001741A1 (es) | Compuestos cíclicos y métodos de uso de estos | |
SV2018005742A (es) | Inhibidores de mcl-1 macrocíclicos para tratar el cáncer | |
NI201900070A (es) | Compuestos heterocíclicos como inmunomoduladores | |
ECSP20069418A (es) | Compuestos heterocíclicos como inmunomoduladores | |
DOP2018000257A (es) | Piridinas sustituidas con heteroarilo y métodos de uso | |
CO2017013708A2 (es) | Macrociclos peptídicos contra acinetobacter baumannii. | |
CR20170563A (es) | Compuestos de benzoxacepina oxazolidinona y métodos de uso. | |
AR111495A1 (es) | Compuestos de imidazo-piperidina fusionada como inhibidores de jak | |
UY35612A (es) | Compuestos de sulfonamida bicíclicos como inhibidores de los canales de sodio | |
CO2019009722A2 (es) | Dendrímeros terapéuticos | |
UY31885A (es) | Derivados de las 1, 3, 5-triazina-2, 4-diaminas-6-sustituidas-n-sustituidas y sales farmacéuticamente aceptables de los mismos, composiciones y aplicaciones. | |
CO2019009423A2 (es) | Inhibidores de mnk sustituidos con piperidina y métodos relacionados con los mismos | |
CL2021001395A1 (es) | Compuestos derivados de panteteínas cíclicas; composición farmacéutica que los comprende; y su uso para aumentar las concentraciones de acetil-coa, para el tratamiento de cáncer, enfermedad inflamatoria, enfermedad neurodegenerativa, esclerosis múltiple, entre otras enfermedades. | |
UY36677A (es) | Compuestos tricíclicos como agentes antineoplásicos | |
UY36875A (es) | Composiciones inhibidoras de bromodominios para el tratamiento de diversas enfermedades | |
ECSP14007965A (es) | Formulaciones de (+)-2-[1-(3-etoxi-4-metoxi-fenil)-2-metansulfonil-etil]-4-acetil aminoisoindolin-1, 3-diona | |
UY35551A (es) | Derivados heteroarilos como inhibidores de aldosterona sintasa | |
AR127470A1 (es) | Inhibidores de lrrk2 | |
CO2018007436A2 (es) | Compuestos de dihidroquinolinsulfonamida de alquilo | |
CO2021013166A2 (es) | Compuestos de hexahidro-1h-pirazino[1,2-a]pirazina para el tratamiento de una enfermedad autoinmunitaria | |
CL2021002946A1 (es) | Un derivado de tetrahidroisoquinolina sustituido como modulador alostérico positivo de d1 | |
CO2021014223A2 (es) | Nuevos compuestos y composiciones farmacéuticas de los mismos para el tratamiento de trastornos inflamatorios | |
CU24627B1 (es) | Derivados de imidazolidin-2-ona sustituidos como inhibidores de prmt5 | |
UY37745A (es) | Compuestos bicíclicos 5,6 fusionados y composiciones para el tratamiento de las enfermedades parasitarias | |
CL2021000282A1 (es) | Inhibidores de ckd8/19 |